• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人尿激酶受体的一个尿激酶敏感区域负责其趋化活性。

A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.

作者信息

Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F

机构信息

Department of Biology and Biotechnology (DIBIT), San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy.

出版信息

EMBO J. 1997 Dec 15;16(24):7279-86. doi: 10.1093/emboj/16.24.7279.

DOI:10.1093/emboj/16.24.7279
PMID:9405357
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1170328/
Abstract

The role of urokinase-type plasminogen activator (uPA) and its receptor (uPAR/CD87) in cell migration and invasion is well substantiated. Recently, uPA has been shown to be essential in cell migration, since uPA-/- mice are greatly impaired in inflammatory cell recruitment. We have shown previously that the uPA-induced chemotaxis requires interaction with and modification of uPAR/CD87, which is the true chemoattracting molecule acting through an unidentified cell surface component which mediates this cell surface chemokine activity. By expressing and testing several uPAR/CD87 variants, we have located and functionally characterized a potent uPAR/CD87 epitope that mimics the effects of the uPA-uPAR interaction. The chemotactic activity lies in the region linking domains 1 and 2, the only protease-sensitive region of uPAR/CD87, efficiently cleaved by uPA at physiological concentrations. Synthetic peptides carrying this epitope promote chemotaxis and activate p56/p59(hck) tyrosine kinase. Both chemotaxis and kinase activation are pertussis toxin sensitive, involving a Gi/o protein in the pathway.

摘要

尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR/CD87)在细胞迁移和侵袭中的作用已得到充分证实。最近研究表明,uPA在细胞迁移中至关重要,因为uPA基因敲除小鼠的炎症细胞募集功能严重受损。我们之前已经证明,uPA诱导的趋化作用需要与uPAR/CD87相互作用并对其进行修饰,uPAR/CD87是通过一种未知的细胞表面成分发挥作用的真正趋化分子,该成分介导这种细胞表面趋化因子活性。通过表达和测试几种uPAR/CD87变体,我们定位并在功能上鉴定了一个有效的uPAR/CD87表位,其模拟了uPA-uPAR相互作用的效应。趋化活性位于连接结构域1和结构域2的区域,这是uPAR/CD87唯一对蛋白酶敏感的区域,在生理浓度下可被uPA有效切割。携带该表位的合成肽可促进趋化作用并激活p56/p59(hck)酪氨酸激酶。趋化作用和激酶激活均对百日咳毒素敏感,表明该途径涉及Gi/o蛋白。

相似文献

1
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.人尿激酶受体的一个尿激酶敏感区域负责其趋化活性。
EMBO J. 1997 Dec 15;16(24):7279-86. doi: 10.1093/emboj/16.24.7279.
2
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).环[19,31][D-半胱氨酸19]-尿激酶型纤溶酶原激活剂19-31是尿激酶型纤溶酶原激活剂与其受体(CD87)相互作用的强效竞争性拮抗剂。
Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150.
3
Structure and function of the urokinase receptor.尿激酶受体的结构与功能。
Thromb Haemost. 1999 Sep;82 Suppl 1:19-22.
4
Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck).可溶性尿激酶受体促进细胞黏附,并且激活p56/59(hck)需要酪氨酸92。
Biochem Biophys Res Commun. 2000 Nov 19;278(2):440-6. doi: 10.1006/bbrc.2000.3818.
5
Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.尿激酶型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂受体介导人干细胞对恶性实体瘤的趋向性。
Stem Cells. 2008 Jun;26(6):1406-13. doi: 10.1634/stemcells.2008-0141. Epub 2008 Apr 10.
6
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.尿激酶受体的蛋白水解切割可替代激动剂诱导的趋化作用。
EMBO J. 1996 Apr 1;15(7):1572-82.
7
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.经表位映射的单克隆抗体作为肿瘤组织中人尿激酶受体功能和形态分析的工具。
Am J Pathol. 1997 Apr;150(4):1231-44.
8
Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro.尿激酶缺陷型和尿激酶受体缺陷型小鼠在体外的中性粒细胞抗菌激活功能受损。
J Leukoc Biol. 2004 Sep;76(3):648-56. doi: 10.1189/jlb.0104023. Epub 2004 Jul 7.
9
Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.通过尿激酶连接肽区域与αvβ5整合素之间的新型相互作用激活尿激酶受体。
J Cell Sci. 2006 Aug 15;119(Pt 16):3424-34. doi: 10.1242/jcs.03067. Epub 2006 Aug 1.
10
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.在基因缺陷小鼠中产生的抗小鼠尿激酶型纤溶酶原激活物受体的鼠单克隆抗体:对体内外受体介导的尿激酶型纤溶酶原激活物活性的抑制作用
Thromb Haemost. 2007 Jun;97(6):1013-22.

引用本文的文献

1
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体:肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
2
Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma.可溶性尿激酶型纤溶酶原激活物受体(suPAR)与成人哮喘疾病转归的关系
J Asthma Allergy. 2022 May 10;15:579-593. doi: 10.2147/JAA.S356083. eCollection 2022.
3
Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.尿激酶受体信号传导对细胞功能的调节:一种机制性观点
Front Cell Dev Biol. 2022 Apr 8;10:818616. doi: 10.3389/fcell.2022.818616. eCollection 2022.
4
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.癌症中针对尿激酶及其受体的治疗策略
Cancers (Basel). 2022 Jan 19;14(3):498. doi: 10.3390/cancers14030498.
5
Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke.可溶性尿激酶型纤溶酶原激活物受体水平与缺血性脑卒中患者残疾和死亡预后中其他炎症因子的相关性
Brain Sci. 2021 Dec 28;12(1):39. doi: 10.3390/brainsci12010039.
6
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
7
Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.可溶性尿激酶型纤溶酶原激活物受体:黑人群体中的遗传变异与心血管疾病风险。
Circ Genom Precis Med. 2021 Dec;14(6):e003421. doi: 10.1161/CIRCGEN.121.003421. Epub 2021 Oct 28.
8
suPAR, a Circulating Kidney Disease Factor.可溶性尿激酶型纤溶酶原激活物受体,一种循环性肾脏疾病因子。
Front Med (Lausanne). 2021 Oct 6;8:745838. doi: 10.3389/fmed.2021.745838. eCollection 2021.
9
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.实验和临床证据支持将尿激酶纤溶酶原激活系统成分用作食管腺癌中具有临床相关性的生物标志物。
Cancers (Basel). 2021 Aug 14;13(16):4097. doi: 10.3390/cancers13164097.
10
Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.纤溶酶原激活物受体在细胞信号转导、固有免疫和炎症中的组装。
Am J Physiol Cell Physiol. 2021 Oct 1;321(4):C721-C734. doi: 10.1152/ajpcell.00269.2021. Epub 2021 Aug 18.

本文引用的文献

1
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.尿激酶型纤溶酶原激活物受体在乳腺癌中的预后意义
Clin Cancer Res. 1995 Oct;1(10):1079-87.
2
uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?尿激酶型纤溶酶原激活物、尿激酶型纤溶酶原激活物受体、纤溶酶原激活物抑制剂-1:蛋白水解、黏附及趋化途径的关键交汇点?
Immunol Today. 1997 Sep;18(9):415-7. doi: 10.1016/s0167-5699(97)01121-3.
3
Cell-surface acceleration of urokinase-catalyzed receptor cleavage.尿激酶催化的受体裂解的细胞表面加速作用
Eur J Biochem. 1997 Jan 15;243(1-2):21-6. doi: 10.1111/j.1432-1033.1997.0021a.x.
4
Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes.原发性T淋巴细胞中整合素依赖性功能性尿激酶受体的诱导
J Clin Invest. 1996 Sep 1;98(5):1133-41. doi: 10.1172/JCI118896.
5
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.在尿激酶型纤溶酶原激活剂(uPA)缺陷型和野生型小鼠中诱导原发性皮肤黑素细胞肿瘤:细胞性蓝痣在uPA缺陷型动物中侵袭但不会进展为恶性黑色素瘤。
Cancer Res. 1996 Aug 1;56(15):3597-604.
6
Regulation of integrin function by the urokinase receptor.尿激酶受体对整合素功能的调节
Science. 1996 Sep 13;273(5281):1551-5. doi: 10.1126/science.273.5281.1551.
7
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.尿激酶受体拮抗剂可抑制同基因小鼠的血管生成和原发性肿瘤生长。
Cancer Res. 1996 May 15;56(10):2428-33.
8
Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.尿激酶是肺部对新型隐球菌炎症反应所必需的。一种小鼠转基因模型。
J Clin Invest. 1996 Apr 15;97(8):1818-26. doi: 10.1172/JCI118611.
9
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.尿激酶受体的蛋白水解切割可替代激动剂诱导的趋化作用。
EMBO J. 1996 Apr 1;15(7):1572-82.
10
Generation and characterization of urokinase receptor-deficient mice.尿激酶受体缺陷小鼠的产生与特性研究
J Clin Invest. 1996 Feb 1;97(3):870-8. doi: 10.1172/JCI118489.